VAS
VRTX icon

Vestmark Advisory Solutions’s Vertex Pharmaceuticals VRTX Stock Holding History

Vestmark Advisory Solutions’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.86M Buy
7,762
+805
+12% +$357K 0.04% 470
2026
Q1 		$3.11M Sell
6,957
-865
-11% -$403K 0.03% 473
2025
Q4 		$3.55M Sell
7,822
-1,606
-17% -$692K 0.05% 391
2025
Q3 		$3.69M Buy
9,428
+665
+8% +$278K 0.07% 275
2025
Q2 		$3.9M Sell
8,763
-3,625
-29% -$1.67M 0.06% 254
2025
Q1 		$6.01M Buy
12,388
+6,595
+114% +$3.07M 0.15% 176
2024
Q4 		$2.33M Sell
5,793
-346
-6% -$160K 0.08% 237
2024
Q3 		$2.86M Buy
6,139
+26
+0.4% +$12.5K 0.11% 207
2024
Q2 		$2.87M Buy
6,113
+4,610
+307% +$2M 0.12% 188
2024
Q1 		$628K Sell
1,503
-2
-0.1% -$845 0.03% 360
2023
Q4 		$612K Sell
1,505
-164
-10% -$60.6K 0.03% 325
2023
Q3 		$580K Sell
1,669
-15,332
-90% -$5.36M 0.04% 280
2023
Q2 		$5.98M Sell
17,001
-219
-1% -$73.8K 0.23% 111
2023
Q1 		$5.43M Sell
17,220
-734
-4% -$220K 0.24% 114
2022
Q4 		$5.18M Sell
17,954
-204
-1% -$62.2K 0.25% 98
2022
Q3 		$5.26M Sell
18,158
-591
-3% -$170K 0.29% 79
2022
Q2 		$5.28M Sell
18,749
-1,024
-5% -$274K 0.3% 74
2022
Q1 		$5.16M Sell
19,773
-209
-1% -$49.6K 0.29% 71
2021
Q4 		$4.39M Sell
19,982
-357
-2% -$69.4K 0.25% 88
2021
Q3 		$3.69M Sell
20,339
-400
-2% -$78.1K 0.25% 94
2021
Q2 		$4.18M Buy
20,739
+1,197
+6% +$250K 0.3% 79
2021
Q1 		$4.2M Buy
19,542
+4,009
+26% +$881K 0.37% 59
2020
Q4 		$3.67M Buy
15,533
+1,712
+12% +$393K 0.41% 52
2020
Q3 		$3.76M Buy
13,821
+2,128
+18% +$587K 0.51% 37
2020
Q2 		$3.4M Buy
11,693
+817
+8% +$222K 0.53% 39
2020
Q1 		$2.59M Sell
10,876
-530
-5% -$122K 0.51% 42
2019
Q4 		$2.5M Sell
11,406
-239
-2% -$48.4K 0.51% 58
2019
Q3 		$1.97M Sell
11,645
-309
-3% -$54.7K 0.32% 86
2019
Q2 		$2.19M Buy
11,954
+97
+0.8% +$17K 0.38% 65
2019
Q1 		$2.18M Buy
+11,857
New +$2.19M 0.39% 64

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vestmark Advisory Solutions's VRTX Position: Q2 2026 in Review

Vestmark Advisory Solutions increased its Vertex Pharmaceuticals (VRTX) stake by 12% in Q2 2026, buying an estimated $357K and bringing the position to 7,762 shares worth $3.86M. The position accounts for 0.04% of the portfolio, ranked #470.

Vestmark Advisory Solutions first reported a position in VRTX in Q1 2019 and has held it in 30 quarters since. The position peaked at $6.01M in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Vestmark Advisory Solutions held 7,762 shares of Vertex Pharmaceuticals worth $3.86M as of Q2 2026.
  • Vestmark Advisory Solutions bought 805 Vertex Pharmaceuticals shares in Q2 2026, an estimated $357K.
  • Vertex Pharmaceuticals made up 0.04% of Vestmark Advisory Solutions's portfolio in Q2 2026, its #470 holding.
  • Vestmark Advisory Solutions first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 30 quarters since.
  • Vestmark Advisory Solutions's Vertex Pharmaceuticals position peaked at $6.01M in Q1 2025.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.